CRDF - Cardiff Oncology, Inc.

-

$undefined

N/A

(N/A)

Cardiff Oncology, Inc. NASDAQ:CRDF Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Its goal is to overcome resistance, improve response to treatment and increase overall survival. The company is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. Cardiff has three clinical programs that have demonstrated the safety and efficacy of onvansertib: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® (bevacizumab) in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 study of onvansertib in combination with Zytiga® (abiraterone)/prednisone in metastatic castration-resistant prostate cancer (mCRPC); and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML). A new Phase 2 trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin and fluorouracil for the second-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC) is planned for initiation in the first half of 2021.

Location: 11055 Flintkote Ave, California, 92121, US | Website: cardiffoncology.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

86.76M

Cash

60.32M

Avg Qtr Burn

-8.017M

Short % of Float

16.94%

Insider Ownership

7.25%

Institutional Own.

26.65%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Data readout

Onvansertib (monotherapy) Details
Cancer, Small cell lung cancer

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Update

Onvansertib + Zytiga (abiraterone) Details
Prostate cancer, Cancer, Castration-resistant prostate cancer

Phase 2

Update

Onvansertib + Paclitaxel Details
Cancer, Triple-negative breast cancer

Phase 1/2

Update

Failed

Discontinued